Today: 11 June 2026
Browse Category

NASDAQ:IGV 4 January 2026

Stock Market Today

  • Live Cattle Futures Edge Higher Amid Mixed USDA Beef Prices
    June 11, 2026, 10:54 AM EDT. Live cattle futures rose by $1.45 to $1.60 across most front months on Wednesday, with December delivery slightly down. Feeder cattle futures gained $2.40 to $2.90 by midday. Open interest increased by 1,293 contracts. Managed money trimmed net long positions in live cattle futures and options by 7,083 contracts, totaling 101,265, while feeder cattle spec funds reduced holdings by 470 contracts. USDA reported a decline in wholesale boxed beef prices, with Choice boxes down $1.68 to $359.36 and Select down $3.15 to $344.88. Federally inspected cattle slaughter rose to an estimated 123,000 head Wednesday, exceeding last week but falling short of last year. The mixed data signals ongoing volatility in cattle markets as traders assess supply and demand factors.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Go toTop